Allay Consulting, a Portland, OR-based firm specializing in cannabis regulatory compliance consulting, has announced a new division to deliver regulatory compliance services in the legal therapeutic psilocybin market in Oregon, as well as other jurisdictions that follow suit. 

It’s not just how much money that is being raised by psychedelic drug companies. It’s HOW they are doing it.

PSYK, the first psychedelics ETF, commences trading today on Canada’s Neo Exchange.

Field Trip continues its U.S. expansion with opening of a new clinic in Atlanta.

Mind Cure announces plans to roll out a line of pre- and post-treatment adaptogen supplements.

Adult-use cannabis sales in Arizona began last Thursday making the state the quickest to move from approval at the ballot box to a functional market.

The world’s first exchange-traded fund for psychedelic-drug companies will debut this week in Toronto, as the investment industry tries to capitalize on rising interest in prospective mental health treatments using the drugs.

The psychedelics reform movement has seen a wave of successes at the state and local level over the past couple years, but a newly formed group says the timing is right to take their activism to the next stage: Congress.

Albert Labs, a privately held psychedelic drug developer, signed a letter of intent (LOI) on January 5 to be acquired by ME Resource Corp (CSE:MEC) (OTC:MEEXF), the latter company announced. 

As trading in psychedelic stocks begins to heat up (again), the emerging psychedelic drug industry is growing rapidly — vertically and horizontally.